ArticleBJUI compass2025
Testosterone levels at diagnosis: A key predictor of overall survival among patients with prostate cancer.
Article in BJUI compass, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Testosterone levels at diagnosis: A key predictor of overall survival among patients with prostate cancer.BJUI compass · 2025Article
- Beyond castration: defining maximal testosterone control in advanced prostate cancer.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: The exact relationship between testosterone levels at diagnosis and prostate cancer (PCa) prognosis remains inadequately explored. The objective was to determine whether serum testosterone levels at the time of PCa diagnosis are associated with overall survival. Patients and Methods: The study cohort involved 2544 PCa patients, divided into three groups; normal (>10.4 nmol/L), grey zone (8.0-10.4 nmol/L) and low (2.0-8.0 nmol/L) serum testosterone groups. Survival outcomes were analysed using Kaplan-Meier curves and Cox regression models. Results: The analysis revealed an increased risk of death among patients with low testosterone levels compared to those with normal levels in uni- (HR = 1.67, 95% CI: 1.37-2.05, Conclusion: Low testosterone at the time of PCa diagnosis is an independent predictor of overall survival. Findings highlight the potential of testosterone for prognostic evaluation in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.